March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Clinical Experience With Sustained-Release Intravitreal Corticosteroid Implants: A Comparison Between The Fluocinolone Acetonide (Retisert) And Dexamethasone (Ozurdex) Implants In Uveitis
Author Affiliations & Notes
  • Cheryl A. Arcinue
    Uveitis and Ocular Immunology, Massachusetts Eye Research & Surgery Institution, Cambridge, Massachusetts
  • C. Stephen Foster
    Uveitis and Ocular Immunology, Massachusetts Eye Research & Surgery Institution, Cambridge, Massachusetts
  • Olga Ceron
    Uveitis and Ocular Immunology, Massachusetts Eye Research & Surgery Institution, Cambridge, Massachusetts
  • Lama Almulki
    Ophthalmology, Massachusetts Eye Res and Surgery Inst, Cambridge, Massachusetts
  • Footnotes
    Commercial Relationships  Cheryl A. Arcinue, None; C. Stephen Foster, None; Olga Ceron, None; Lama Almulki, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6286. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cheryl A. Arcinue, C. Stephen Foster, Olga Ceron, Lama Almulki; Clinical Experience With Sustained-Release Intravitreal Corticosteroid Implants: A Comparison Between The Fluocinolone Acetonide (Retisert) And Dexamethasone (Ozurdex) Implants In Uveitis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6286.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of the fluocinolone acetonide (Retisert) implant compared with the dexamethasone (Ozurdex) implant in patients with noninfectious uveitis.

Methods: : Chart review of patients at the Massachusetts Eye Research and Surgery Institution (MERSI) was done and patients were selected and matched according to age, sex, and type of uveitis. Twenty-seven eyes received either the fluocinolone acetonide (n=16) or dexamethasone (n=11) implant. The primary efficacy outcome was a comparison of the recurrence rate of uveitis after implantation, with follow-up ranging from 6 months to 2 years.

Results: : There were no significant differences in the average age (p=0.56), sex (p=1.0), and pre-implantation lens status (p=0.10) of patients in the two groups. The diagnosis of CME (p=1.0) and glaucoma (p=0.31) were also not different between the two groups. Majority of cases were idiopathic panuveitis, with 36.4% in the Ozurdex group and 31.3% in the Retisert group. Recurrence rate in the Retisert group was 1.8 per 100 person-months or 18 per 1000 person-months while it is 7 per 1000 person-months in the Ozurdex group. Those in the Retisert group were 2.6 times more at risk of recurrence than those in the Ozurdex group, however, this was not statistically significant (p=0.41).

Conclusions: : The dexamethasone intravitreal implant seems comparable to the fluocinolone acetonide intravitreal implant in preventing recurrence of noninfectious uveitis. Although the findings suggest that those in the Retisert group were 2.6 times more at risk of recurrence than those in the Ozurdex group, this was not found to be statistically significant.

Keywords: uveitis-clinical/animal model • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×